Latin America Autoinjectors Market

Market Overview

The Latin America Autoinjectors market size witnessed significant growth and is expected to grow at a CAGR of around 12.5% during the forecast period (2023-2030).

Highlights

• Anaphylaxis dominates the market by therapy.
• Disposable dominates the market by type.
• Homecare dominates the market by end-user.

A medical device known as an autoinjector is used to administer a specified dose of medication, usually by injection. It normally consists of a pre-filled syringe, a needle, and a spring-loaded mechanism that delivers the drug swiftly and easily with the push of a button. It is made to be simple to use by the patient or caregiver. Frequently, autoinjectors treat, among others, diseases, including multiple sclerosis, arthritis, and allergies. They can lessen the danger of unintentional needle stick injuries and are frequently utilized in emergency settings where quick medicine administration is required.

Market Dynamics

Latin America Autoinjectors Market Drivers

Increasing Chronic Disease Prevalence

The increased incidence of chronic conditions like diabetes, rheumatoid arthritis, multiple sclerosis, and asthma in Latin America drives the demand for autoinjectors. The prevalence of diabetes has been gradually increasing in Latin America, which has increased the demand for autoinjectors. A projected 62 million adults in Latin America will have diabetes by 2045, according to the International Diabetes Federation (IDF), up from an estimated 38 million in 2019. The need for autoinjectors as a dependable and user-friendly drug administration method is rising as the prevalence of diabetes and other chronic diseases in Latin America rises.

Latin America Autoinjectors Market Restraints

Use of Generic Injections and Tablets

Due to regulatory actions promoting access to affordable healthcare and cost-saving measures, the availability and use of generic drugs have increased recently. For instance, because of their cheaper costs compared to their branded equivalents, generic drugs are frequently given and preferred by healthcare professionals, insurance companies, and consumers in nations like Brazil and Mexico. The widespread use of generic injections and tablets may constrain the expansion of the autoinjector market in Latin America.

Latin America Autoinjectors Market Opportunities

Growing Healthcare Expenditure

Brazil's greatest Latin American economy has seen healthcare spending rise significantly. Brazil is reforming its healthcare system to improve access, quality, and efficiency. Most Brazilians use Sistema Único de Saúde (SUS), the public healthcare system. The government's investment in hospitals, clinics, and primary healthcare centers shows its commitment to improving healthcare access. As healthcare costs rise, innovative therapy and medical devices are prioritized. With their precision and patient convenience, autoinjectors can benefit from this rising healthcare cost.

Regional Analysis

The Latin American autoinjectors market is analyzed by country in Brazil, Argentina, and the Rest of Latin America. Brazil dominated the market and is expected to grow at a CAGR of 13.2% during the forecast period.

Latin American autoinjectors will grow moderately over the predicted period. Autoinjector use increases as chronic diseases rise. Diabetes is the 2nd leading cause of mortality in Mexico and one of the top 10 worldwide, according to the WHO. Due to their simplicity, insulin injection pens are the most used method. Biologics also boost market growth. Drug innovation and biological patent expiration help pharmaceutical companies expand.

The elderly population also boosts market demand. NCBI research estimates 71 million 60-year-olds in Latin America and the Caribbean, 11.2% of the population. The Caribbean (13.2%) has the greatest 60+ population, followed by South America (11.7%) and Central America (9.6%). Argentina, Mexico, and Colombia are investing more in this region's main market, Brazil. Brazil develops innovative, inexpensive autoinjectors.

Autoinjector manufacturers work with multinationals. Regional growth also depends on government backing. Mexico leads the autoinjectors market in revenue after Brazil. Technology and research centers also boost industry expansion.

Self-administration leads to autoinjectors replacing syringes. Autoinjectors are also employed in oncology for orphan illnesses and hormone therapy for several dosages. Instead of weekly medical sessions for injections, patients can easily give the drug at home. During the projection period, the requirement for customized or patient-centric devices and needle stick injury prevention will drive market growth.

However, this region still uses generic injections and tablets, limiting the market growth. Autoinjectors cost more than syringes, but patients and the healthcare system benefit from self-administration. This tendency is expanding over Latin American marketplaces from Western countries. This medication will be needed more in the future, increasing demand for these devices and their manufacturing solutions. Over the projection period, the necessity for customized or patient-centric devices and needle stick injury prevention drives the market growth.

Segmental Analysis

The Latin American autoinjectors market is segmented based on therapy, type, end-user, and country.

The market is further segmented by therapy into Anaphylaxis, Rheumatoid Arthritis, Psoriasis, migraines, Cardiovascular-diseases, and others.

The Anaphylaxis segment dominates the market and is expected to grow at a CAGR of 12.7% during the forecast period.

The market is further segmented by type into Disposable, Reusable.

Disposable dominated the market and is expected to register a CAGR of 12.7% over the forecast period.

The market is further segmented by end-user into Hospitals and clinics, home care, and others.

The home care segment dominates the market and is expected to grow at a CAGR of 13.2% during the forecast period.

Recent Developments

• May 2023- B.D. (Becton, Dickinson, and Company), a leading global medical technology company launched a new cell sorting instrument with two breakthrough technologies that allow researchers to discover more cell information than was previously possible in flow cytometry experiments.
• April 2023- Nutriband Inc. and Kindeva Drug Delivery ("Kindeva") selected the target AVERSATM formulation for commercial scale manufacturing process development for the Company's patented lead product, AVERSATM Fentanyl, an abuse-deterrent fentanyl transdermal system.